Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Punit R Bhardwaj

Montse Llinas-Brunet

Murray D Bailey

Teddy Halmos

Nathalie Goudreau

Elise Ghiro

Jean Rancourt

Pasquale Forgione

Sylvie Goulet

Vida J Gorys

Josee Bordeleau

Marc-André Poupart

Marc-Andre Poupart

Compounds of formula (I): wherein B, X, R, L, L, L, R, Rand Rare defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.

Hepatitis C inhibitor compounds

The invention relates to compounds of formula (I) wherein R', R, R, R, R, R, Y, n and m are as defined herein. The compounds are useful for the treatment and prevention of hepatitis C viral infections in mammals by inhibiting HCV NS3 protease. The invention further relates to azalactone compounds of the formula (III) which can be reacted with an amide anion to produce the compounds of formula (I). 

Hepatitis C inhibitor peptide analogs

Compounds of formula (I): wherein R, R, R, R, R, Y, n and m are as defined herein. The compounds are useful as inhibitors of HCV NS3 protease.

Compounds of formula I: wherein D, R, R, L, L, L, Rand Rare defined herein; or a pharmaceutically acceptable salt thereof, useful as inhibitors of the HCV NS3 protease.

Macrocyclic peptides active against the hepatitis C virus

Compounds of formula (I): wherein R, R, R, R, n and m are as defined herein. The compounds are useful as inhibitors of HCV NS3 protease.

Growing community of inventors

Laval, Canada

Punit R Bhardwaj